Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Statin-Free in palliative care: could stopping cholesterol drugs improve quality of life?

NCT ID NCT07543432

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether it is safe and beneficial for people with advanced cancer to stop taking statins, which are cholesterol-lowering drugs often used for prevention. Researchers will follow 80 patients in palliative care for 12 weeks, monitoring cholesterol levels, muscle strength, fatigue, and quality of life. The goal is to gather knowledge that could lead to better guidelines on when to stop preventive medications near the end of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deprescribing statins (stopping statin medication)
What this could lead to
If successful, this could provide clear guidelines on when to safely stop statins in advanced cancer patients, reducing side effects and unnecessary medication.
What could go wrong
This is a small pilot study with only 80 participants, so results may not apply broadly. There is a risk of cardiovascular events after stopping statins, which the study monitors closely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria intervention arm: * ≥ 18 years, * "No"-answer to the "surprise question" 1 year: Would you be surprised if this patient died in the next year? (this is a common and validated prognostic tool in palliative care) * advanced cancer * ongoing palliative care at the the unit study units * treatment with statins ≥ 3 months for primary or secondary prevention before study inclusion Inclusion Criteria control-group: * Same as above but no statin treamnet Exclusion Criteria:h * Cognitive impairment * Does not understand the Swedish language * Known homozygous or double heterozygous familial hypercholesterolemia * Active cardiovascular disease or sufficient risk of active cardiovascular disease that requires ongoing medication with statins (assessed by a specialist in cardiology) * myositis symptoms * Other contraindications to deprescribe statins.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ASIH Stockholm Södra

    RECRUITING

    Stockholm, 12559, Sweden

  • Stockholms Sjukhem Pallitive Care

    RECRUITING

    Stockholm, 11219, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.